Preliminary Programme 13th IMW 2011

8/8/2019 Preliminary Programme 13th IMW 2011

1/12

13THIMW

PARIS2011

May 3-6, 2011

Paris, Carrousel du Louvre

Abstracts Submission: from June 2010 to January 2011

Registration: Opening June 2010

PRELIMINARYPROGRAM

ME

13h InnIn

MYM WKShP


2/12

Welcome to Paris

Dear Colleagues and Friends,It is both a privilege and an honour to invite you to attend the XIIIth International Myeloma Workshop to be held inParis from May 3 to 6, 2011.In continuation with the previous organizers of this important biannual event, we aim to provide a compelling

scientic programme highlighting emerging advances in our understanding of the biology and treatment of mye-loma disease. We also aim to stimulate lively debate discussion within the myeloma community and to contributeto efcient diffusion of medical information.Striving to further improve the quality of the meeting through various initiatives is another exciting task for us. Thelocation of the Workshop, in the Carrousel du Louvre which is right in the city centre, will ensure that you all enjoyboth the meeting and the fascinating city of Paris.

We are very much looking forward to welcoming you to Paris in May 2011!

Jean-Paul Fermand Thierry Facon Philippe Moreau

C F BSCS

Submit a abstract based o your scietic work i oe of te followig categories:

- Section A: Basic Biology- Section B: Boe Disease (icludig Imagig)- Section C: Cliical Studies (icludig rasplatatio)- Section D: Precliical Studies ad new Drugs- Section E: pidemiology, Progostic Factors, Quality of ife, Disease Complicatios ad reatmet oxicities- Section F: ter Plasma Cell Dyscrasias

Abstracts will have to be submitted directly on the Internet.They will be mainly considered for poster presentation, only a few abstracts will be chosen for oral presentation.Accepted abstracts will be published in the Haematologica Journal (supplement).

geda

Submission opening: Jue 2010Submission deadline: Jauary 10, 2011Notication of acceptance: Marc 2011

For further information on abstracts submission, please visit the website:

www.myeloma-paris2011.com

SUBMI n BSC BF JnUY 10, 2011!


3/12

PIMInY PGMM

uesday May 3 Wedesday May 4 ursday May 5 Friday May 6

8:00

0:00

0:30

2:30

4:00

6:00

6:30

7:30

8:30

9:00

9:15

20:30

21:30

23:00

newly diagosed MM < 65 yrs:facts & questios

Chair:D. Reece & V. Hungria

How I treat?V. Rajkumar

What are the current asked questions?Cooperative groups

CelgeeSymposium

The Continuum of Care for theMultiple Myeloma Patient

Chair:K. Anderson &J.-L. Harousseau

Molecular patways /

geetics

Chair:H. Avet-Loiseau & M. Chesi

PnInG KCoffee break

Visit of exhibition & posters area

ucVisit of exhibition & posters area

Coffee breakVisit of exhibition & posters area





Boe disease: frompysiopatology to treatmet

Chair:R. Bataille & B. Durie

Waldestroms awardIntroduced byR. Kyle

Welcome receptio at teMuse du ouvre

Debate I:Post ig dose terapy, otig,

cosolidatio or maiteace?

Chair: J. Blad ;M. Attal & J.-P. Fermand

new boe ad biologicalexploratio teciques iplasma cell disorders

Chair:P. Greipp & R. Hjek

Myeloma cast epropaty &

amyloidosis

Chair:G. Merlini & R. Comenzo

prIM cologySymposium supported by

novartis cology

Strategies in Evolution:Bone Targeted Therapy for Myeloma

Debate II:Sould we treat some patiets

wit stage I MM?

Chair:M. Gertz ;

V. Mateos & S. Lonial

Pleary abstract sessio I

Chair:M. Cavo & G. Gahrton

Invited speakers:H. Lokhorst &D. Joshua

Moocloal immuoglobuli

ad te erve, Waldes-troms macroglobuliemia

Chair:S. Treon & M. Delforge

Closig ceremoy

Introducing IMW 2013:K. ShimizuPlasma cell Biology

Chair:B. Klein & N. Munshi

hig-risk etities of MM:

from biology to treatmet

Chair:K. Stewart & M. Kuehl

new drugs ad terapeutic

approaces

Chair:J. San Miguel &M. Boccadoro

newly diagosed MM > 65 yrs:facts & questios

Chair:R. Alexanian & A. Palumbo

How I treat?B. Barlogie

What are the current asked questions?Cooperative groups

Milleium akeda& Jasse-Cilag

Symposium

Proteasome inhibition in multiplemyeloma and its clinical implications

Cosesus report

Chair:N. Munshi

Diagnosis criteria & criteria for

treatment and retreatment

Supportive care

Pleary abstractsessio II

Chair:P. Richardson & M. Attal




4/12

USDY MY 3, 2011

I 10:00 - 10:30 OPENING TALK

I 10:30 - 12:30 MOLECLAR PATHWAYS / GENETICSChair:H. Avet-Loiseau- FRA & M. Chesi- USA

Mai lecture: Germinal center and post germinal center differentiation:the cradle of MM ..................................................................................................................................................................... R. Dalla-Favera- USA

The different subtypes of MM ..................................................................................................................................................... R. Fonseca- USAThe genetic progression of MM....................................................................................................................................... H. Avet-Loiseau- FRAMai lecture: MicroRNAs in MM .................................................................................................................................................... C. Croce- USAPanel discussion

I 12:30 - 14:00 LuNch


I 14:00 - 16:00 PLASMA CELL BIOLOGYChair:B. Klein- FRA & N. Munshi- USA

Introduction lecture: The PR system.............................................................................................................................. A.-H. Lee- USA

Cytokine patways: which one to target? ...................................................................................................................................... B. Klein- FRA

mTOR complex pathway in MM........................................................................................................................................

A. Lichtenstein- USARole of syndecan-1 ............................................................................................................................................................... R.-D. Sanderson- USA

Panel discussion

I 16:00 - 16:30 cOffEE BrEAK


I 16:30 - 18:30 BONE DISEASE: FROM PHYSIOPATHOLOGY TO TREATMENTChair:R. Bataille- FRA& B. Durie- USA

Introduction lecture: .......................................................................................................................................................... G.-D. Roodman- USA............................................................................................................................................................................................................................ S. Yaccoby- USA............................................................................................................................................................................................................................... N. Giuliani- ITA

............................................................................................................................................................................................................................. B.-P. Ayati- USA

............................................................................................................................................................................................................................ P. Tassone- GBR

............................................................................................................................................................................................................... K. Vanderkerken- BEL

Panel discussion

I 18:30 - 19:15 WALDENSTROMS AWARDIntroduced byR. Kyle- USA

I 20:30 - 23:00 WELCOME RECEPTION AT THE MSE D LORE

PIMInY PGMM


5/12

WDnSDY MY 4, 2011

I8:00 - 10:00NEWLY DIAGNOSED MM < 65 YRS: FACTS & ESTIONSChair:D. Reece- CAN& V. Hungria- BRA

how I treat? ......................................................................................................................................................................................... V. Rajkumar- USA

Wat are te curret asked questios?................................................................................................................... Cooperative groups

EMN ........................................................................................................................................................................................ P. Sonneveld- NED

CTN-BMT........................................................................................................................................................................................ S. Giralt- USA

Pethema...................................................................................................................................................................................... L. Rosiol- ESP

MRC ............................................................................................................................................................................................ G. Morgan- GBR

IFM-DFCI ................................................................................................................................................................................... P. Moreau- FRA

Arkansas ................................................................................................................................................................................. B. Barlogie- USA



I10:30 - 12:30 CELGENE SYMPOSIMe Cotiuum of Care for te Multiple Myeloma PatietChair:K. Anderson- USA & J.-L. Harousseau- FRA

Welcome ad itroductio:The changing dynamic of multiple myeloma treatment .............................................................................. J.-L. Harousseau- FRA

Mechanisms of action and disease: intercellular eventsand immunomodulation ................................................................................................................................................................ S. Lentzsch- USA

Mechanisms of action and disease: immune synapse ............................................................................................. M.-D. Davis- GBR

Optimizing current therapeutic options for relapsed/refractorymultiple myeloma ............................................................................................................................................................... M.-A. Dimopoulos- GRE

The evidence supporting continuous therapy in multiple myeloma ......................................................................... S. Giralt- USA

From bench to bedside: combination regimens in the present and futuremanagement of multiple myeloma ................................................................................................................................ K.-C. Anderson- USA

Close .................................................................................................................................................................................................. K.-C. Anderson- USA

I 12:30 - 14:00 LuNch



6/12

I 14:00 - 16:00 HIGH-RIS ENTITIES OF MM: FROM BIOLOGY TO TREATMENTChair:K. Stewart- USA& M. Kuehl- USA

t(4& 14) and genomic instability in high-risk MM ...................................................................................................... L. Bergsagel- USA

The biochemical role of the histone methyltransferase MMSET in MM .................................................................... A. Licht- SUI

Whole Genome Sequencing in high-risk MM ..................................................................................................................... K. Stewart- USAWhat is GEP-defined high-risk MM? ........................................................................................................................... J. Shaughnessy- USAThe implications of high-risk MM to therapy ........................................................................ G. Morgan- GBR& H. Einsele- GERPanel discussion

I 16:00 - 16:30 cOffEE BrEAKVisit of exhibition & posters area

I16:30 - 17:30 DEBATE I:POST HIGH DOSE THERAPY, NOTHING, CONSOLIDATION OR MAINTENANCEChair:J. Blad- ESP; M. Attal- FRA & J.-P. Fermand- FRA

I 17:30 - 19:00 NEW BONE AND BIOLOGICAL EXPLORATION TECHNIESIN PLASMA CELL DISORDERSChair:P. Greipp- USA& R. Hjek- CZE

Introduction lecture:Bone imaging in MM: old scaffolds and new avenues ............................................................................. M.-A. Dimopoulos- GRE

Whole-body MRI in MM ........................................................................................................................................................ H. Goldschmidt- GER

Pamidronate: Can the Dose be Lowered? ............................................................................................................................ P. Gimsing- DNE

Zoledronic Acid in the Management of MM ........................................................................................................................ J.-A. Child- GBR

Osteonecrosis of the Jaw ........................................................................................................................................................................ N. Raje- USA

Should we use bone markers? ....................................................................................................................................................... E. Terpos- GREPanel discussion

I 19:00 - 20:30 MYELOMA CAST NEPHROPATHY & AL AMYLOIDOSISChair:G. Merlini- ITA& R. Comenzo- USA

Introduction lecture: New therapeutic approaches in AL ............................................................................. M.-B. Pepys- GBR

Management of AL amyloidosis in 2011 ................................................................................................................................... G. Merlini- ITA

Myeloma cast nephropathy ...................................................... N. Leung- USA& F. Bridoux- FRA &C.-A. Hutchinson- GBR

I20:30 - 21:30 PRIME ONCOLOGY SYMPOSIM SPPORTED BY NOARTIS ONCOLOGYStrategies in Evolution: Bone Targeted therapy for Myeloma


7/12

hUSDY MY 5, 2011

I8:00 - 10:00 NEWLY DIAGNOSED MM > 65 YRS: FACTS & ESTIONSChair:R. Alexanian- USA& A. Palumbo- ITA

how I treat? ........................................................................................................................................................................................... B. Barlogie- USA

Wat are te curret asked questios? .................................................................................................................. Cooperative groups

GIMEMA ................................................................................................................................................................................... A. Palumbo- ITA

Pethema .................................................................................................................................................................................. M. Mateos- ESP

GMMSG ....................................................................................................................................................................................... C. Straka- GER

Hovon/Nordic .......................................................................................................................................................................... A. Waage- NOR

IFM ................................................................................................................................................................................................... T. Facon- FRA

MRC ............................................................................................................................................................................................... F. Davies- GBR



I10:30 - 12:30 MILLENNIM TAEDA & JANSSEN-CILAG SYMPOSIMBiological rationale for proteasome inhibition in multiple myelomaand its clinical implicationsChair & speakers to be announced

Biological basis of proteasome inhibition in MMImpact of proteasome inhibition in the treatment of MM

pdate on clinical studies on proteasome inhibition in MM

Clinical management of peripheral neuropathy in MM

I 12:30 - 14:00 LuNch



8/12

I 14:00 - 16:00 NEW DRGS AND THERAPETIC APPROACHESChair:M. Boccadoro- ITA & J. San Miguel- ESP

Introduction lecture................................................................................................................................................................... K. Anderson- USA

Preclinical basis for 2nd generation proteasome inhibitors ..................................................................................... D. Chauhan- USA

Carfilzomib and other proteasome inhibitors: Clinical data ..................................................................... A.-J. Jakubowiak- USA

New Imids ........................................................................................................................................................................................................ M. Lacy- USA

Hypomethylating agents in MM ...................................................................................................... J. San Miguel- ESP& E. Ocio- ESP

Monoclonal antibodies in the treatment of MM ......................................................................................................... S. Jagannath- USA

Panel discussion



I16:30 - 17:30 DEBATE II:SHOLD WE TREAT SOME PATIENTS WITH STAGE I MM?Chair:M. Gertz- USA;V. Mateos- ESP&S. Lonial- USA

I17:30 - 19:00 PLENARY ABSTRACT SESSION IChair:M. Cavo- ITA & G. Gahrton- SWE

Invited speakers: H. Lokhorst- NDE& D. Joshua- AUS

I 19:00 - 20:30 MONOCLONAL IMMNOGLOBLIN AND THE NERE, WALDENSTROMSMACROGLOBLINEMIAChair:S. Treon- USA& M. Delforge- BEL

Neuropathy in monoclonal gammopathy ................................................................................................................... E. Nobile-Orazio- ITA

Poems syndrome .......................................................................................................................................................................... A. Dispenzieri- USA

pdate in the treatment of WM ............................................................................................................. S.Treon- USA& V. Leblond- FRA


9/12

FIDY MY 6, 2011

I8:00 - 10:00 CONSENSS REPORTChair:N. Munshi- USA

Diagnosis criteria & criteria for treatment and retreatmentSupportive care including vaccination and infection prophylaxis (E. Anaissie- USA), management of anemia(H. Ludwig- AUT), vein thrombosis (A. Palumbo- ITA,), and bone disease (G.-D. Roodman- USA)



I10:30 - 12:30 PLENARY ABSTRACT SESSION IIChair:P. Richardson- USA& M. Attal- FRA

Invited speaker:A. Spencer- AUS

I 12:30 - 15:00 CLOSING CEREMONYIntroducing IMW 2013 ...................................................................................................................................................................... K. Shimizu- JPN


10/12

CUS DU UV F Pn

CCSS

Carrousel

du Louvre

layoRsialaPervuoLudesuM

1 7

seireliuT

1

iloviR-ervuoL

1

esuMyasrOd

Carrousel

du Louvre

A6

A1

A3

A4

GARE

DAUSTERLITZ

GARE

DE LYON

GARE

DU NORD

GARE

DE LEST

GARE

MONTPARNASSE

GARE

SAINT LAZARE

PORTE DORLANS PORTE DITALIE

PORTE DELA CHAPELLE

A14

LA DFENSE

PORTEMAILLOT

PORTEDAUTEUIL

PORTE

DE BAGNOLET

PORTEDE BERCY

A13

ROISSY CHARLES DE GAULLE

INTERNATIONAL AIRPORT

ORLY INTERNATIONAL

AIRPORT

secalp08

secalp006

RUETIART

RUETIART

ECNARTNEERVUOL

VselrahCllaHecnartne

iloviRedeur99

ellaSertNeL

sqm0091

ellaStolffuoS

sqm529

emroleDsqm0532

ellaS leirbaG

reyoFsqm0021

nedraGlesuorraC

edacragnippohS

edacragnippohS

e*ninazzeM

sqm006

Conference Room

Exhibition / Hospitality suits/ Catering

*Mezzanine: meeting rooms and posters


11/12

Venue: Carrousel du Louvre99 rue de Rivoli

75001 Paris - FRANCE

Dates: May 3-6, 2011

Ofcial Web site: www.myeloma-paris2011.com

Registration: Before March 31, 2011:Reduced fees for early registration: 700 eurosReduced fees for early registration for IMS Member: 550 euros

From April 1st, 2011:Regular fees: 800 euros

Reduced fees for IMS Member: 650 euros

Ofcial language: English

Social event - Welcome Reception: Muse du LouvreMay 3, 2011

Professional Congress Organizer - Europa Organisation

Project Manager: Michal Sertain [email protected]

Partnership Sales Representative: Afaf [email protected]

Registration [email protected]

Hotel reservation Carlson Wagonlit [email protected]

INFORMATION


12/12

INFORMATION

Committees - rgaizig CommitteeJean-Paul FERMAND - Thierry FACON - Philippe MOREA

Under the auspices of the International Myeloma Society and its Board of Directors

Robert A. YLE (President) ania HNGRIA

enneth C. ANDERSON (ice-President) Nikhil MNSHIDouglas E. JOSHA (Secretary) Antonio PALMBOMorie Abraham GERTZ (Treasurer) Jess F. SAN MIGEL

Brian G.M. DRIE azuyuki SHIMIZJean-Luc HAROSSEA Pieter SONNEELD

French Scientic Advisory Committee

Martine AMIOT Jean-Luc HAROSSEABertrand ARNLF Cyrille HLIN

Michel ATTAL Bernard LEIN

Herv AET LOISEA Catherine PELLAT-DECENYNCRgis BATAILLE Claire MATHIOT

International Scientic Advisory Committee

Raymond ALEXANIANBart BARLOGIE

Peter Leif BERGSAGELJoan BLAD

Mario BOCCADOROMichele CAOFaith DAIES

Meletios A. DIMOPOLOSHermann EINSELE

Rafael FONSECAGsta GAHRTON

Sergio GIRALTNicola GILIANI

Sundar JAGANNATH

Henk M. LOHORSTHeinz LDWIGMaria-ictoria MATEOSGiampaolo MERLINIGareth J. MORGANS. incent RAJMARDonna E. REECEPaul G. RICHARDSONJohn D. SHAGHNESSYAndrew SPENCEReith STEWARTSteven TREONarin ANDERERENAnders WAAGE

Platinium sponsors

Bronze sponsors

Others sponsors

Preliminary Programme 13th IMW 2011

Documents

Transcript of Preliminary Programme 13th IMW 2011